ISRG vs. ZBH: Which Robotic Surgery Stock Offers Better Upside Now?

The global surgical robotics market is projected to grow to $9.6 billion by 2033 at a 9.3% CAGR. Intuitive Surgical (ISRG) maintains a dominant 60% global share in soft-tissue surgery, driven by its da Vinci platform and strong recurring revenue, with a 2025 growth outlook of 15.5-17%. Zimmer Biomet (ZBH) is actively expanding its orthopedic robotics portfolio through strategic acquisitions and innovation, showing steady growth. Both stocks have declined YTD (ISRG -15.5%, ZBH -12.9%) due to tariff uncertainty and rising costs; however, the article identifies ZBH as a more attractive investment due to its lower valuation (Zacks Rank #2 Buy) compared to ISRG's higher valuation (Zacks Rank #4 Sell).

Analysis

The surgical robotics market is poised for significant expansion, projected to grow from $4.31 billion in 2024 to $9.6 billion by 2033 at a 9.3% CAGR. Within this market, Intuitive Surgical (ISRG) and Zimmer Biomet (ZBH) present contrasting investment profiles. ISRG maintains a dominant position with approximately 60% of the global market share, driven by its da Vinci systems and a robust recurring revenue model that accounts for 85% of its total revenue. The company has raised its 2025 procedure growth outlook to 15.5-17%, fueled by rapid adoption of its new da Vinci 5 system and over 50% year-over-year procedure growth on its Ion endoluminal platform. However, ISRG faces near-term headwinds, including a 15.5% year-to-date share price decline, gross margin pressure from the da Vinci 5 launch, and a premium valuation that remains above the industry average despite the correction. Conversely, Zimmer Biomet is solidifying its position in the orthopedic robotics segment through its ROSA platform and strategic acquisitions. ZBH has demonstrated steady execution with Q2 growth of 4.0% in hips and 4.9% in S.E.T., and its knee business is projected to grow at a 3.5% CAGR through 2027. Despite lowering its earnings outlook due to weak sales and rising costs, which contributed to a 12.9% YTD stock decline, ZBH trades at a significant valuation discount to the industry and holds a Zacks 'A' Value score. Both companies are impacted by tariff uncertainty and rising costs, creating near-term pressure on profitability.

Key Decisions for Investors

• Given its attractive valuation, a Zacks Rank of #2 (Buy), and steady execution in the orthopedic market, Zimmer Biomet presents a compelling value-oriented opportunity for investors willing to tolerate a lowered near-term earnings outlook.
• Despite strong fundamental growth drivers and a raised 2025 outlook of 15.5-17%, investors should exercise caution with Intuitive Surgical due to its premium valuation, near-term gross margin pressures, and a Zacks Rank of #4 (Sell), which could signal risk of further price correction.
• Investors should weigh the distinct profiles of each company: ISRG offers higher growth and market dominance at a premium price, while ZBH provides a value entry point into the growing robotics market with more modest growth expectations.
• Monitor developments related to tariffs and input costs, as these macroeconomic factors are cited as primary near-term risks impacting profitability and stock performance for both companies.